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Objectives: We aimed to assess the symptom burden and health related quality of 
life in patients with idiopathic lung fibrosis. MethOds: Patients have been consec-
utively enrolled in an ongoing prospective non-interventional registry in Germany, 
investigating clinical characteristics, clinical management practices and quality of 
life. IPF diagnoses were in agreement with the international IPF guideline published 
in 2011. Clinical parameters and treatment practice were recorded by the physi-
cian. Patients filled out the EQ-5D-5L, St George’s Respiratory Questionnaire (SGRQ), 
WHO-5 and the UCSD shortness of breath (SOB) scale. The time trade off (TTO) score 
was calculated for the EQ-5D. Results: To date (04 June 2014), 421 patients with IPF 
have been enrolled in the registry (mean age 68.6±9.5; 77% male). The mean six-min-
ute walk distance was 271±200, mean % of predicted forced vital capacity was 72±20 
and the mean % predicted DLCO was 35±16. Patients were treated with oral steroids 
(22.1%, as monotherapy in 7.1%); N-acetylcysteine (34.8%), pirfenidone (47.2%), and 
long-term O2 therapy (34.4%). The physician rated the disease in 35.6% as stable, 
in 31.1% as slowly progressing and in 11.9% as rapidly progressing. One in four 
patients described their current state of health as at least good, and every fifth as 
poor. The mean EQ-5D TTO score was 0.8±0.2. 45% of the patients showed depressive 
symptoms based on the WHO-5. The mean SGRQ sum score was 47.7±20.1 describing 
difficulties with breathing in the previous 3 months. Higher EQ-5D TTO scores were 
significantly associated with a lower number of comorbid diseases (r= -0.31), higher 
6-minute walk distance (r= 0.20), higher FVC % pred (r= 0.27), less depression (r= 0.66) 
and lower SGRQ scores (r= -0.72). cOnclusiOns: The IPF patients in this large reg-
istry had a more severe disease, a higher symptom burden and more compromised 
quality of life compared to recent randomised controlled trials.
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Objectives: The Nighttime Symptoms of COPD Instrument (NiSCI) and Early 
Morning Symptoms of COPD Instrument (EMSCI) were developed to support treat-
ment benefit endpoints in global clinical trials. Translations that were conceptually 
equivalent to the English source version and easily understood by the target country 
populations were required. The purpose of this study was to translate and assess 
conceptual equivalence of the NiSCI and EMSCI for use in 14 countries: Austria, 
Bulgaria, Canada, Czech Republic, France, Germany, Hungary, Italy, Lithuania, The 
Netherlands, Poland, South Africa, Spain, and United Kingdom. MethOds: The 
NiSCI and EMSCI were translated following ISPOR guidelines for linguistic valida-
tion of PRO measures (Wild et al., 2005) using the universal approach discussed in 
the second Task Force Report (Wild et al., 2009). The universal English, Spanish and 
French versions were previously translated (Eremenco et al., 2012). For the remain-
ing languages, two forward translations by native translators, reconciliation of the 
forwards, one back-translation by an English-speaker fluent in the target language, 
and final reconciliation by a native speaking language coordinator were conducted 
for both measures. Harmonization was performed to ensure conceptual equiva-
lence across languages. Interviews were conducted with five native-speaking COPD 
patients for each language/country combination. Interview data were analyzed to 
assess linguistic and cultural validity in each language and confirm conceptual 
equivalence. Results: Mean age of the sample (N= 80) was 60 years (range 41-83) 
and 54% were male. The translations were well understood and considered relevant, 
with patients raising only minor issues during interviews. Changes were made to the 
universal French (chest congestion), Hungarian (wheezing, chest congestion), Italian 
(chest congestion, moderately), and Lithuanian (instructions, wheezing, shortness 
of breath, experienced) following the patient interviews. cOnclusiOns: All trans-
lated versions of the NiSCI and EMSCI in this study were found to be conceptually 
equivalent and acceptable for use in the 14 countries evaluated.
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Objectives: Usability testing of electronic Patient-Reported Outcomes (ePRO) 
instruments is typically conducted during instrument development, in the lan-
guage/country of origin. It has been suggested that usability testing also be per-
formed during the translation process. It is unclear whether this additional step 
is necessary. In this study, usability testing was conducted as part of the linguis-
tic validation process in Simplified Chinese (China), German (Germany), French 
(France), Russian (Russia), and Spanish (Universal, tested in Chile, Spain, and US) 
for the Exacerbations of Chronic obstructive pulmonary disease Tool (EXACT), an 
e-PRO developed and tested in English (US). MethOds: The translation process 
followed ISPOR guidelines (Wild et al., 2005). Cognitive interviews were conducted 
with 2-3 native-speaking COPD respondents per language/country combination 
in 2008. Subjects completed the EXACT in paper-pen screenshot format and were 
interviewed for translation validation. Subsequently they were instructed to use a 
PDA (Tungsten E2; CRF, Inc.) to complete the first 5 EXACT items and were inter-
viewed regarding device usability. Interviewers rated subjects’ ability to use the 
device. Results: Subjects (N= 20) were 45-84 years, 60% male, and 60% with second-
ary education or less. Most (n= 18) had not used a PDA previously; all (n= 20) reported 
oids (76.7%); inhaled-anticholinergic (70.7%); mucolitycs (19.4%); xanthine (7.3%); 
oral-corticosteroids (1.3%). BDI: grade 2. Primary outcome: RCT cohorts: there was 
no difference between control and intervention A and there were statistically 
significative differences between intervention B versus control (p< 0.0001), NNT= 3.22 
(IC95%, 2.27-5.88) and versus intervention A, NNT= 4.16 (IC95%, 2.63-10). In the PPS 
cohorts: there was a difference (p< 0.0001) between intervention B versus interven-
tion A, NNT= 3.22 (IC95%, 2.32-5.55). The preferences enhanced a 6.7% the correct 
inhalation technique. cOnclusiOns: The performance of a correct inhalation 
Technique improves with monitor training. The patients´ preferences enhance the 
efficacy of intervention.
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Objectives: To test the efficacy of two educational interventions to improve the 
inhalation techniques per device in patients with COPD and the influence of patient´ 
preference. MethOds: Design: Multicenter patients´ preference trial or compre-
hensive cohort design ISRCTN15106246. Patients: 465 COPD patients (to detect a 
difference between groups of 25%, 80% statistical power, 95% confidence level, 40% 
expected losses), with inhaled treatment, written consent. Non-probabilistic con-
secutive sampling. Allocation: Patients without strong preferences for a treatment 
are randomised: RCT group (block randomization), and those with strong prefer-
ences are given their choice: PPS group. Variables: Primary outcomes: Performance of 
correct inhalation technique. Independent variables: sex, age, Baseline dyspnea index 
(BDI), Functional status (forced spirometry). Interventions: Interv-A: Written infor-
mation. A leaflet with correct inhalation technique. Interv-B: Interv-A + individual 
training (by instructors). Follow-up: 3 month, visits: baseline (V0), 1 month (V1), 
3 month (V2). Statiscal analysis: Mean, frequency, 95% confidence interval. Intention 
to treat analysis. Results: Males (91.4%), mean age 69.8 years (CI95%, 69.00-70.59); 
FEV1 (mean)= 55.91% (IC95%, 53.62-58.2), mixed respiratory pattern (65.9%). Severity 
stage: 15.7% mild, 44.1% Moderate, 40.3% Severe. BDI: grade 2. Devices use: 67.3% 
Handihaler (Hd), 54.8% Turbuhaler (Th), 31.8% Accuhaler (Acc), 26.9% pMDI. Correct 
Inhalation technique: hd: RCT-control: 11.7% V0,10% (V2); RCT-intervA: 10.9%, 17.5%; 
RCT-IntervB: 7.4%, 62.3% p< 0.0001. Th: RCT-control: 22% V0, 16.7% (V2); RCT-intervA: 
8.7%, 24.4%; RCT-IntervB: 7.5 %, 57.5% p< 0.0001. acc: RCT-control: 16.1% V0, 25% (V2); 
RCT-intervA: 17.9%, 23.1%; RCT-IntervB: 11.5%, 74.1% p< 0.0001. pmdi: RCT-control: 
6.9% V0, 3.6% (V2); RCT-intervA: 12.5%, 19%; RCT-IntervB: 8.3%, 34.6% p= 0.025. 
There were statistically differences for all devices only in the intervention B arms 
(p< 0.0001). The preferences enhanced 1% for Handihaler, 12.7% for Accuhaler, 4.6% 
for Turbuhaler, 15.4% for pMDI the correct inhalation technique. cOnclusiOns: 
The performance of a correct inhalation technique improves with monitor training 
for all devices. The patients´ preferences enhance the efficacy.
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Objectives: To identify characteristics of dry powder inhalers (DPIs) considered 
important by asthma and chronic obstructive pulmonary disease (COPD) patients, 
in order to select attributes and attribute-levels for a discrete choice experi-
ment. MethOds: Qualitative data was collected from a literature review performed 
to determine which inhaler attributes impact inhaler satisfaction and adherence 
among asthma and COPD patients using DPIs. Focus groups with asthma and COPD 
patients were conducted in France, with patients asked to cite and rate important 
features of their inhaler. Qualitative analysis of the transcripts was performed 
following International Society For Pharmacoeconomics and Outcomes Research 
(ISPOR) guidelines. Results: Results of the literature review revealed no overall 
consensus on the importance of different inhaler attributes in relation to inhaler 
satisfaction and adherence across studies. The most frequently reported attributes 
were: overall ease-of-use, low inspiratory flow requirements, presence of a dosing 
feedback mechanism, ergonomics of the inhaler mouthpiece, ease with which the 
device can be kept hygienic and the ease with which the medicinal dose can be pre-
pared. Four discussion groups were held, with thirty patients participating. Overall, 
the degree to which the inhaler can optimise treatment convenience appeared 
to be the most important attribute to patients. In agreement with results of the 
literature review, patients also rated the following inhaler attributes as being impor-
tant: size of the dose counter, ability to keep the mouthpiece hygienic, ergonomics 
of the inhaler mouthpiece, presence of a dosing feedback mechanism, ease with 
which a dose can be prepared, low inspiratory flow requirements. cOnclusiOns: 
Results of this study provide an insight inhaler attributes most valued by asthma 
and COPD patients. Patients described their ideal inhaler to be small, with an ergo-
nomic mouthpiece and an easy to use dose preparation mechanism, and providing 
enough medicine for at least a month of treatment.
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